Johnson & Johnson on Thursday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations, and lifted its full-year guidance as sales from the company’s medtech business jumped.
The medtech division provides devices for surgeries, orthopedics and vision. The company is benefitting from a rebound in demand for non-urgent surgeries among older adults, who deferred those procedures during the pandemic.
Here’s how J&J results compared with Wall Street expectations, based on a survey of analysts by Refinitiv:
- Earnings per share: $2.80 adjusted, vs. $2.62…